• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $PRCT

    PROCEPT BioRobotics Corporation

    Subscribe to $PRCT
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: procept-biorobotics.com

    Recent Analyst Ratings for PROCEPT BioRobotics Corporation

    DatePrice TargetRatingAnalyst
    12/2/2024$105.00Overweight
    Morgan Stanley
    11/14/2024$95.00Hold
    Jefferies
    8/11/2023$42.00Overweight
    Piper Sandler
    5/31/2023Outperform
    William Blair
    10/31/2022Neutral
    BTIG Research
    10/25/2022$58.00Buy
    Truist
    9/2/2022$49.00Overweight
    Wells Fargo
    7/15/2022$47.00Overweight
    KeyBanc Capital Markets
    6/23/2022$53.00Buy
    B. Riley Securities
    3/9/2022$48.00 → $42.00Buy
    B of A Securities
    See more ratings

    PROCEPT BioRobotics Corporation Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

      SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

      11/14/24 1:28:32 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

      SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

      11/12/24 5:01:10 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

      SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

      11/4/24 1:31:19 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by PROCEPT BioRobotics Corporation (Amendment)

      SC 13D/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

      5/22/24 9:31:23 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by PROCEPT BioRobotics Corporation (Amendment)

      SC 13D/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

      5/7/24 9:45:23 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by PROCEPT BioRobotics Corporation

      SC 13G - PROCEPT BioRobotics Corp (0001588978) (Subject)

      2/14/24 10:04:39 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation (Amendment)

      SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

      2/13/24 5:12:14 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation (Amendment)

      SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

      2/9/24 9:49:30 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by PROCEPT BioRobotics Corporation

      SC 13G - PROCEPT BioRobotics Corp (0001588978) (Subject)

      1/26/24 5:25:22 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation (Amendment)

      SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

      2/14/23 1:18:03 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care

    PROCEPT BioRobotics Corporation Press Releases

    Fastest customizable press release news feed in the world

    See more

    PROCEPT BioRobotics Corporation Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June

      SAN JOSE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of management will present at four upcoming investor conferences in May and June. 2025 Bank of America Health Care Conference Location – Las Vegas, NVFireside Chat – Wednesday, May 14 at 3pm PT / 6pm ET 45th Annual William Blair Growth Stock Conference Location – Chicago, ILPresentation – Wednesday, June 4 at 10am CT / 11am ET 2025 Jefferies Global Healthcare Conference Location – New York City, NYFireside Chat – Thursday, June 5 at 8:45m ET

      4/29/25 4:03:00 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops

      Presentations underscore long-term clinical outcomes, safety and durability in BPH treatment Attendees invited to experience hands-on HYDROS Robotic System demonstrations SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT)  ("PROCEPT"), a surgical robotics company whose mission is to revolutionize BPH treatment globally, today announced an extensive lineup of scientific presentations and interactive workshops at the 2025 American Urological Association (AUA) Annual Meeting, taking place April 26–29 in Las Vegas, Nevada. Clinical data presentations will highlight long-term outcomes, safety and durability of Aquablation® therapy for BPH. Th

      4/24/25 4:03:00 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

      SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $69.2 million for the first quarter of 2025, an increase of 55% compared to the prior year period in 2024U.S. handpiece and consumables revenue of 38.0 million for the first quarter of 2025, an increase of 61% compared to the prior year period in 2024Sold 43 new robotic sy

      4/24/25 7:00:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas

      SAN JOSE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company, whose mission is to revolutionize BPH treatment globally, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Aria Resort in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time. Guests are encouraged to register in advance by clicking HERE. Registration is recommended to secure your spot. Members of PROCEPT BioRobotics' management team presenting include: Reza Zadno – Chief Executive OfficerKevin Waters – Chief Financial OfficerSham Shiblaq – Chief Commercial O

      4/10/25 4:03:00 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation

      SAN JOSE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, today announced its Aquablation therapy was evaluated in the independent, investigator-initiated WATER III trial. This study compared Aquablation therapy to laser enucleation for treating large prostates, with results presented in the prestigious Game-Changer session at the European Association of Urology (EAU) 2025 Annual Congress in Madrid, Spain. WATER III is an international, prospective, multicenter study comparing Aquablation therapy to laser enucleation in prosta

      3/24/25 8:00:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada

      SAN JOSE, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Venetian Hotel in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time. Members of PROCEPT BioRobotics' management team presenting include: Reza Zadno – Chief Executive OfficerKevin Waters – Chief Financial OfficerSham Shiblaq – Chief Commercial OfficerBarry Templin – Chief Technology Officer Clinical perspectives will also be

      3/14/25 8:00:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 Results

      SAN JOSE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the fourth quarter and year ended December 31, 2024. Recent Highlights Total revenue of approximately $68.2 million for the fourth quarter of 2024, an increase of 57% compared to the prior year periodU.S. system revenue of $27.6 million for the fourth quarter of 2024, an increase of 67% compared to the prior year periodSold 60 new robotic systems in the U.S. in the fourth quarter of 2024 at a blended average selling price of a

      2/25/25 4:02:00 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics® to Report Fourth Quarter 2024 Financial Results on February 25, 2025 and Attend the TD Cowen 45th Annual Healthcare Conference and the 2025 Leerink Partners Healthcare Conference

      SAN JOSE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the fourth quarter of 2024 after market close on Tuesday, February 25, 2025. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/q33jvv92 Dial-in registration for sell-side research analysts

      2/7/25 8:00:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on PROCEPT BioRobotics (NASDAQ: PRCT)

      NOTE TO EDITORS: The Following Is an Investment Opinion Issued by Spruce Point Capital Management Provides Evidence That Procept's Vision of Addressing "All Prostates" Is Highly Exaggerated Raises Serious Concerns About Procept's Market Size Estimates, Procedure Competitiveness, and Aquablation Adoption Hurdles Questions Procedure Safety, the Quality Track Record of Procept Equipment, and the Value-Add of and Market Reception to the Company's New HYDROS System Highlights Disturbing Data Points Suggesting Growing Business Challenges, Relevance of Key Metrics, and Financial Model Concerns Estimates That Procept Shares Face 30%-60% Long-Term Potential Downside Risk Given Its Niche So

      1/16/25 9:00:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024

      SAN JOSE, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 36th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Wednesday, December 4 at 8:30 a.m. Eastern Time. A live webcast of each event, as well as an archived recording, will be available on the "Investors" section of the company's website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 da

      11/26/24 4:05:00 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • President, CEO Zadno Reza sold $312,404 worth of shares (5,475 units at $57.06), decreasing direct ownership by 3% to 173,070 units (SEC Form 4)

      4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

      3/19/25 4:16:41 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • EVP, CFO Waters Kevin sold $41,825 worth of shares (733 units at $57.06), decreasing direct ownership by 0.67% to 107,991 units (SEC Form 4)

      4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

      3/19/25 4:15:38 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • EVP, Chief Comm. Officer Shiblaq Hisham sold $14,094 worth of shares (247 units at $57.06), decreasing direct ownership by 0.39% to 63,133 units (SEC Form 4)

      4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

      3/19/25 4:08:29 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • EVP, CLO, CORP. SEC. Nouri Alaleh sold $18,031 worth of shares (316 units at $57.06), decreasing direct ownership by 0.51% to 61,473 units (SEC Form 4)

      4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

      3/19/25 4:04:26 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • EVP, CLO, CORP. SEC. Nouri Alaleh sold $223,230 worth of shares (3,641 units at $61.31), decreasing direct ownership by 6% to 61,789 units (SEC Form 4)

      4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

      3/10/25 4:31:08 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • EVP, Chief Comm. Officer Shiblaq Hisham sold $219,980 worth of shares (3,588 units at $61.31), decreasing direct ownership by 5% to 63,380 units (SEC Form 4)

      4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

      3/10/25 4:29:48 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • EVP, CFO Waters Kevin sold $224,517 worth of shares (3,662 units at $61.31), decreasing direct ownership by 3% to 108,724 units (SEC Form 4)

      4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

      3/10/25 4:28:21 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • President, CEO Zadno Reza sold $975,810 worth of shares (15,916 units at $61.31), decreasing direct ownership by 8% to 178,545 units (SEC Form 4)

      4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

      3/10/25 4:26:51 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • EVP, CLO, CORP. SEC. Nouri Alaleh was granted 12,958 shares, increasing direct ownership by 25% to 65,430 units (SEC Form 4)

      4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

      3/5/25 5:36:04 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • EVP, Chief Comm. Officer Shiblaq Hisham was granted 11,107 shares, increasing direct ownership by 20% to 66,968 units (SEC Form 4)

      4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

      3/5/25 5:34:29 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care

    PROCEPT BioRobotics Corporation Leadership Updates

    Live Leadership Updates

    See more
    • Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

      SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th

      10/28/24 7:00:00 AM ET
      $ISRG
      $PRCT
      $SNBR
      $SWAV
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
      Home Furnishings
    • Jupiter Endovascular Exits Stealth With $21M in New Financing to Fund Pivotal Trial for Pulmonary Embolism

      Carl J. St. Bernard Appointed as Chief Executive Officer Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions, announced today that it has exited stealth mode with a $21 million new round of financing. Sonder Capital was a key participant in the round that included participation from multiple strategic investors. The funding will be used to support the company's upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology. "For decades, the

      8/15/24 10:00:00 AM ET
      $ISRG
      $PRCT
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • Sonder Capital Appoints Kate Garrett as Managing Partner to Lead Next Generation of Growth

      Co-founders and industry luminaries Dr. Fred Moll and Jay Watkins will assume the newly created role of Co-chair as firm closes its latest fund, Futures II Sonder Capital, a leading venture capital firm focused on identifying teams and technologies that will transform healthcare, today announced the appointment of firm Co-founder Kate Garrett as Managing Partner. In this pivotal role, Garrett will spearhead Sonder's next phase of growth as the firm closes Sonder Futures II, its second early stage fund. With Garrett becoming Managing Partner, Sonder Co-founders and industry luminaries Fred Moll, M.D. and Jay Watkins will maintain their roles as partners and assume the newly created posit

      4/2/24 8:00:00 AM ET
      $ISRG
      $PRCT
      $SWAV
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • CTS Corporation Announces Appointment of Amy M. Dodrill to its Board of Directors

      LISLE, Ill., Feb. 08, 2024 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS), a leading global designer and manufacturer of custom engineered solutions that "Sense, Connect and Move," today announced that Amy M. Dodrill has been appointed to its board of directors, effective February 8, 2024, and will serve as a member of the nominating, governance and sustainability and technology and transactions committees. Ms. Dodrill comes to CTS with over 25 years of experience in medical and technology companies and a proven track record of successfully leading and profitably growing global businesses serving key end markets. Ms. Dodrill most recently served as President of Baxter's Global Surgical

      2/8/24 5:30:00 PM ET
      $CTS
      $PRCT
      Electrical Products
      Technology
      Medical/Dental Instruments
      Health Care
    • Neptune Medical Appoints Dr. Fred Moll as Chairman of the Board

      Neptune Medical, a leading innovator in medical technology, is pleased to announce the appointment of Dr. Fred Moll as Chairman of the Board. Dr. Moll, a seasoned entrepreneur and influential figure in the medical technology industry considered to be the father of medical robotics, brings a wealth of experience and expertise to Neptune Medical. Dr. Fred Moll is currently a Managing Partner at Sonder Capital, a venture capital firm focused on investing in breakthrough healthcare technologies. His illustrious career includes founding Intuitive Surgical, a pioneer in robotic-assisted minimally invasive surgery, and Auris Health, which was acquired by Johnson & Johnson. In addition to his r

      11/20/23 8:00:00 AM ET
      $PRCT
      $SWAV
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics Appoints Mary Garrett to Board of Directors

      REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the appointment of Mary Garrett to its Board of Directors. Ms. Garrett most recently served on the board of Hillrom Corporation which was acquired by Baxter International Inc. in December 2021. Ms. Garrett was the governance committee chair and served on the audit committee of Hill-Rom. She also previously served as a board member and was on the audit committee of Ethan Allen Interiors, Inc. Prior to these roles and her retirement in 2015, Ms. Garrett was the

      1/4/22 7:00:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics Appoints Elisabeth Sandoval to Board of Directors

      REDWOOD CITY, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the appointment of Elisabeth Sandoval to its Board of Directors. Ms. Sandoval currently serves as a consultant to the pharmaceutical industry and is a member of the board of directors of Intersect ENT, Inc., Satsuma Pharmaceuticals, Inc. and Vyne Therapeutics, Inc. She is also on the Board of privately held Alastin Skincare. Ms. Sandoval previously served as the Chief Commercial Officer and Executive Vice President of Corporate Strategy at Alder Biopharmaceuti

      10/26/21 7:00:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care

    PROCEPT BioRobotics Corporation Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley initiated coverage on PROCEPT BioRobotics with a new price target

      Morgan Stanley initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $105.00

      12/2/24 7:01:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Jefferies initiated coverage on PROCEPT BioRobotics with a new price target

      Jefferies initiated coverage of PROCEPT BioRobotics with a rating of Hold and set a new price target of $95.00

      11/14/24 8:28:45 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Piper Sandler initiated coverage on PROCEPT BioRobotics with a new price target

      Piper Sandler initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $42.00

      8/11/23 7:19:06 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • William Blair initiated coverage on PROCEPT BioRobotics

      William Blair initiated coverage of PROCEPT BioRobotics with a rating of Outperform

      5/31/23 7:35:42 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • BTIG Research initiated coverage on PROCEPT BioRobotics

      BTIG Research initiated coverage of PROCEPT BioRobotics with a rating of Neutral

      10/31/22 7:49:04 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Truist initiated coverage on PROCEPT BioRobotics with a new price target

      Truist initiated coverage of PROCEPT BioRobotics with a rating of Buy and set a new price target of $58.00

      10/25/22 6:48:01 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Wells Fargo initiated coverage on PROCEPT BioRobotics with a new price target

      Wells Fargo initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $49.00

      9/2/22 7:17:17 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • KeyBanc Capital Markets initiated coverage on PROCEPT BioRobotics with a new price target

      KeyBanc Capital Markets initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $47.00

      7/15/22 7:56:25 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities initiated coverage on PROCEPT BioRobotics with a new price target

      B. Riley Securities initiated coverage of PROCEPT BioRobotics with a rating of Buy and set a new price target of $53.00

      6/23/22 12:21:46 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • B of A Securities reiterated coverage on PROCEPT BioRobotics with a new price target

      B of A Securities reiterated coverage of PROCEPT BioRobotics with a rating of Buy and set a new price target of $42.00 from $48.00 previously

      3/9/22 10:35:51 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care

    PROCEPT BioRobotics Corporation Financials

    Live finance-specific insights

    See more
    • PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

      SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $69.2 million for the first quarter of 2025, an increase of 55% compared to the prior year period in 2024U.S. handpiece and consumables revenue of 38.0 million for the first quarter of 2025, an increase of 61% compared to the prior year period in 2024Sold 43 new robotic sy

      4/24/25 7:00:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada

      SAN JOSE, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Venetian Hotel in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time. Members of PROCEPT BioRobotics' management team presenting include: Reza Zadno – Chief Executive OfficerKevin Waters – Chief Financial OfficerSham Shiblaq – Chief Commercial OfficerBarry Templin – Chief Technology Officer Clinical perspectives will also be

      3/14/25 8:00:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 Results

      SAN JOSE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the fourth quarter and year ended December 31, 2024. Recent Highlights Total revenue of approximately $68.2 million for the fourth quarter of 2024, an increase of 57% compared to the prior year periodU.S. system revenue of $27.6 million for the fourth quarter of 2024, an increase of 67% compared to the prior year periodSold 60 new robotic systems in the U.S. in the fourth quarter of 2024 at a blended average selling price of a

      2/25/25 4:02:00 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics® to Report Fourth Quarter 2024 Financial Results on February 25, 2025 and Attend the TD Cowen 45th Annual Healthcare Conference and the 2025 Leerink Partners Healthcare Conference

      SAN JOSE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the fourth quarter of 2024 after market close on Tuesday, February 25, 2025. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/q33jvv92 Dial-in registration for sell-side research analysts

      2/7/25 8:00:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance

      SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2024. Recent Highlights Total revenue of $58.4 million for the third quarter of 2024, an increase of 66% compared to the prior period in 2023U.S. handpiece and consumables revenue of $29.6 million for the third quarter of 2024, an increase of 74% compared to the prior period in 2023Sold 45 robotic systems in the U.S. in the third quarter of 2024

      10/28/24 7:00:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024

      SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2024 before market open on Monday, October 28, 2024. The Company's management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/yhamkcsz Dial-in registration for sell-side re

      10/9/24 4:04:00 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy

      SAN JOSE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced FDA 510(k) clearance of its next-generation platform, the HYDROS™ Robotic System. Leveraging insights from over 50,000 procedures, HYDROS features FirstAssist AI™ treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. HYDROS is designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan for better clinical outcomes. "We are pleased to bring the H

      8/21/24 7:00:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics® Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue and EBITDA Guidance

      SAN JOSE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2024. Recent Highlights Total revenue of $53.4 million for the second quarter of 2024, an increase of 61% compared to the prior period in 2023U.S. handpiece and consumables revenue of $27.3 million for the second quarter of 2024, an increase of 101% compared to the prior period in 2023Sold 47 robotic systems in the U.S. in the second quarter of 2024U.S. system and rental revenue of $17.

      8/1/24 4:03:00 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024

      SAN JOSE, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2024 after market close on Thursday, August 1, 2024. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/qsztnzfu/ Dial-in registration for sell-side research

      7/15/24 4:03:00 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

      SAN JOSE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2024. Recent Highlights Total revenue of $44.5 million for the first quarter of 2024, an increase of 83% compared to the prior year period in 2023U.S. handpiece and consumables revenue of $23.6 million for the first quarter of 2024, an increase of 101% compared to the prior year period in 2023Sold 38 U.S. robotic systems in the first quarter of 2024U.S. system and rental revenue of

      5/1/24 7:00:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care

    PROCEPT BioRobotics Corporation SEC Filings

    See more
    • SEC Form 10-Q filed by PROCEPT BioRobotics Corporation

      10-Q - PROCEPT BioRobotics Corp (0001588978) (Filer)

      5/2/25 4:51:16 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by PROCEPT BioRobotics Corporation

      DEFA14A - PROCEPT BioRobotics Corp (0001588978) (Filer)

      4/25/25 4:28:36 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by PROCEPT BioRobotics Corporation

      DEF 14A - PROCEPT BioRobotics Corp (0001588978) (Filer)

      4/25/25 4:26:51 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)

      4/25/25 9:03:07 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)

      4/24/25 7:06:01 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by PROCEPT BioRobotics Corporation

      144 - PROCEPT BioRobotics Corp (0001588978) (Subject)

      3/6/25 6:42:25 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 filed by PROCEPT BioRobotics Corporation

      S-8 - PROCEPT BioRobotics Corp (0001588978) (Filer)

      2/28/25 6:09:35 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by PROCEPT BioRobotics Corporation

      10-K - PROCEPT BioRobotics Corp (0001588978) (Filer)

      2/27/25 5:00:54 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)

      2/25/25 4:07:39 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)

      10/31/24 4:02:27 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care